HANGZHOU, China – July 20, 2026 – While Generative AI continues to dominate global technology headlines, a quiet revolution is unfolding away from the immediate spotlight. Alibaba Group is actively bridging the gap between theoretical research and clinical reality by transforming advanced artificial intelligence into a powerful tool for global public health.
Through its global research initiative, DAMO Academy, Alibaba has successfully moved beyond the industry trend of “trapping cutting-edge tech in research papers.” Instead, the company has deployed a world-class medical AI early screening platform—DAMOMED (known domestically as Da Yi Zhi Ying)—which demonstrates how combining routine, non-contrast CT scans with deep-learning algorithms can make life-saving early cancer detection widely accessible.
“We firmly believe that the greatest technological innovations should never be locked away in a lab,” said Jiaping Li, Vice President of Cloud Intelligence Strategic Development at Alibaba Group. “Instead, they must serve as sharp tools to address real-world pain points. Our core driving force remains leveraging computing power and AI to push the boundaries of human capability.”
Conquering the “King of Cancers” via Medical Inclusivity
The cornerstone of Alibaba’s medical AI portfolio is its breakthrough PANDA (Pancreatic Cancer Early Detection with Artificial Intelligence) model. Traditionally, detecting pancreatic cancer—notoriously dubbed the “King of Cancers”—requires expensive, highly complex contrast-enhanced CTs or MRIs, making large-scale screening virtually impossible at primary care clinics.
Alibaba’s medical AI team broke traditional medical conventions by training a deep-learning model capable of spotting microscopic, early-stage lesions in ordinary, non-contrast CT scans. The PANDA model facilitates a unique “single scan, multiple screenings” workflow. When a patient undergoes a routine, everyday CT scan for completely unrelated acute symptoms like pneumonia, the AI runs seamlessly in the background to automatically evaluate the patient for pancreatic, colorectal, esophageal, and gastric cancers, as well as checking for bone density loss and cardiovascular risks.
The real-world validation of this technology has already saved lives. During a routine checkup, the system flagged a 75-year-old female patient after analyzing a low-dose, non-contrast chest CT. The AI correctly identified main pancreatic duct dilation and a potential mass in the head of the pancreas. Following radical surgical resection, pathology confirmed a tiny pancreatic cancer where the malignant tissue measured just 1 millimeter—effectively buying the patient the critical window needed for a total cure.
This milestone research was published in the prestigious journal Nature Medicine and highlighted as a scientific research milestone in Stanford University’s AI Index Report.
Proven Accuracy Across Critical Screenings
The efficiency of DAMOMED is backed by rigorous dataset performance metrics, maintaining high accuracy across several distinct medical screening areas:
·Pancreatic Cancer: Specificity 99.9% | Sensitivity 92.9% | AUC 0.99
·Colorectal Cancer: Specificity 98.8% | Sensitivity 91.8% | AUC 0.99
·Esophageal Cancer: Specificity 98.0% | Sensitivity 90.1% | AUC 0.98
·Acute Aortic Syndrome: Specificity 99.2% | Sensitivity 94.2% | AUC 0.99
Global Social Value and Grassroots Deployment
Recognized globally for its social impact, Alibaba’s AI medical efforts earned the company a spot on Fortune’s “Change the World” list for the sixth time. Alibaba is currently bridging the healthcare inequality gap via two major global initiatives:
1.Grassroots Healthcare: Public-welfare pilot programs have been successfully deployed across regional and county-level hospitals in China (including Lishui, Jingning, Kaihua, and Shengsi), proving that high-end AI screening is highly viable even in resource-scarce environments.
2.International Collaboration: After presenting the multi-cancer screening technology at the United Nations’ AI for Good Global Summit, Alibaba established cooperative intentions with the World Health Organization (WHO) and the Ministry of Health of Antigua and Barbuda to deliver low-cost, high-efficiency AI screening solutions to developing nations.
“Disease knows no borders, and exceptional technological breakthroughs should have no barriers,” Li Jiaping emphasized. “If cutting-edge technology only benefits a handful of elite medical centers, it loses its greatest potential to change the world.”
Empowering, Not Replacing, the Medical Workforce
Addressing industry anxieties regarding AI displacing human clinicians, Alibaba maintains a collaborative view of the technology.
“Our position is crystal clear: AI is not here to replace doctors; it is here to empower them,” stated Li. “Physicians face massive daily patient volumes, which naturally leads to visual fatigue. AI functions like an untiring, highly knowledgeable super-assistant, filtering out noise in the background and capturing incredibly elusive, millimeter-level lesions. Ultimately, the diagnosis, the treatment decisions, and the essential human empathy given to the patient will always belong to the doctor.”
Moving forward, Alibaba and DAMO Academy are committed to expanding the frontiers of healthcare tech into decision intelligence and genomics, working toward a future where world-class preventative care is universally accessible.
Media Contact
Company Name: Alibaba Group
Contact Person: Li Jiaping
Email: Send Email
Country: China
Website: www.alibabagroup.com
Media gallery
